{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T14:02:23Z","timestamp":1789221743819,"version":"build-2803163510"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,17]],"date-time":"2023-01-17T00:00:00Z","timestamp":1673913600000},"content-version":"am","delay-in-days":322,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thrombosisresearch.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Thrombosis Research"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.thromres.2022.01.011","type":"journal-article","created":{"date-parts":[[2022,1,14]],"date-time":"2022-01-14T02:09:49Z","timestamp":1642126189000},"page":"1-5","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"special_numbering":"C","title":["JAK2 allele burden is correlated with a risk of venous but not arterial thrombosis"],"prefix":"10.1016","volume":"211","author":[{"given":"Simon","family":"Soudet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaelle","family":"Le Roy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Estelle","family":"Cadet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audrey","family":"Michaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Morel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean Pierre","family":"Marolleau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie Antoinette","family":"Sevestre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.thromres.2022.01.011_bb0005","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.bcmd.2018.09.003","article-title":"Modest contribution of JAK2 V617F allele burden to the occurrence of major thrombosis in polycthemia vera and essential thrombocythemia","volume":"73","author":"Trifa","year":"2018","journal-title":"Blood Cells Mol. Dis."},{"issue":"2","key":"10.1016\/j.thromres.2022.01.011_bb0010","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.thromres.2014.11.006","article-title":"The JAK2 V617F mutational status and allele burden may be related with the risk of venous thromboembolic events in patients with Philadelphia-negative myeloproliferative neoplasms","volume":"135","author":"Borowczyk","year":"2015","journal-title":"Thromb. Res."},{"issue":"13","key":"10.1016\/j.thromres.2022.01.011_bb0015","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1182\/blood-2013-03-460154","article-title":"Myeloproliferative neoplasms and thrombosis","volume":"122","author":"Barbui","year":"2013","journal-title":"Blood."},{"issue":"22","key":"10.1016\/j.thromres.2022.01.011_bb0020","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1056\/NEJMcp1816082","article-title":"Essential thrombocythemia","volume":"381","author":"Tefferi","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.thromres.2022.01.011_bb0025","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1200\/JCO.2005.07.062","article-title":"Vascular and neoplastic risk in a large cohort of patients with polycythemia vera","volume":"23","author":"Marchioli","year":"2005","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.thromres.2022.01.011_bb0030","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1160\/th15-04-0326","article-title":"Splanchnic vein thrombosis and myeloproliferative neoplasms: molecular-driven diagnosis and long-term treatment","volume":"115","author":"De Stefano","year":"2016","journal-title":"Thromb. Haemost."},{"issue":"4","key":"10.1016\/j.thromres.2022.01.011_bb0035","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1002\/ajh.24293","article-title":"Validation of the revised international prognostic score of thrombosis for essential thrombocythemia (IPSET-thrombosis) in 585 Mayo Clinic patients","volume":"91","author":"Haider","year":"2016","journal-title":"Am. J. Hematol."},{"issue":"2","key":"10.1016\/j.thromres.2022.01.011_bb0040","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/s41408-020-0289-2","article-title":"Validation of the IPSET score for thrombosis in patients with prefibrotic myelofibrosis","volume":"10","author":"Guglielmelli","year":"2020","journal-title":"Blood Cancer J."},{"issue":"2","key":"10.1016\/j.thromres.2022.01.011_bb0045","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1056\/NEJMoa1701719","article-title":"Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease","volume":"377","author":"Jaiswal","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.thromres.2022.01.011_bb0050","first-page":"10(436)","article-title":"Increased neutrophil extracellular trap formation promotes thrombosis in myeloproliferative neoplasms","volume":"11","author":"Wolach","year":"2018","journal-title":"Sci. Transl. Med."},{"issue":"2","key":"10.1016\/j.thromres.2022.01.011_bb0055","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1056\/NEJMoa035572","article-title":"Efficacy and safety of low-dose aspirin in polycythemia vera","volume":"350","author":"Landolfi","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.thromres.2022.01.011_bb0060","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s13045-016-0242-9","article-title":"Bleeding, thrombosis, and anticoagulation in myeloproliferative neoplasms (MPN): analysis from the German SAL-MPN-registry","volume":"9","author":"Kaifie","year":"2016","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.thromres.2022.01.011_bb0065","article-title":"Thrombosis among 1537 patients with JAK2V617F -mutated myeloproliferative neoplasms: risk factors and development of a predictive model","volume":"28","author":"Zhang","year":"2020","journal-title":"Cancer Med."},{"issue":"2","key":"10.1016\/j.thromres.2022.01.011_bb0070","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/s41408-018-0054-y","article-title":"The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion","volume":"8","author":"Barbui","year":"2018","journal-title":"Blood Cancer J."},{"issue":"1","key":"10.1016\/j.thromres.2022.01.011_bb0075","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41408-017-0042-7","article-title":"Polycythemia vera treatment algorithm 2018","volume":"8","author":"Tefferi","year":"2018","journal-title":"Blood Cancer J."},{"issue":"1","key":"10.1016\/j.thromres.2022.01.011_bb0080","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1038\/s41408-017-0041-8","article-title":"Essential thrombocythemia treatment algorithm 2018","volume":"8","author":"Tefferi","year":"2018","journal-title":"Blood Cancer J."},{"issue":"5","key":"10.1016\/j.thromres.2022.01.011_bb0085","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s11899-017-0400-3","article-title":"Risk factors for and management of MPN-associated bleeding and thrombosis","volume":"12","author":"Martin","year":"2017","journal-title":"Curr. Hematol. Malig. Rep."},{"issue":"2","key":"10.1016\/j.thromres.2022.01.011_bb0090","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1111\/cas.14270","article-title":"Mutation status and burden can improve prognostic prediction of patients with lower-risk myelodysplastic syndromes","volume":"111","author":"Jiang","year":"2020","journal-title":"Cancer Sci."},{"issue":"2","key":"10.1016\/j.thromres.2022.01.011_bb0095","doi-asserted-by":"crossref","first-page":"31","DOI":"10.2478\/bjmg-2019-0021","article-title":"Evaluation of the JAK2V617F mutational burden in patients with Philadelphia chromosome negative myeloproliferative neoplasms: a single-center experience","volume":"22","author":"Popova-Labachevska","year":"2019","journal-title":"Balk. J. Med. Genet."},{"issue":"2","key":"10.1016\/j.thromres.2022.01.011_bb0100","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1002\/ajh.25677","article-title":"Splanchnic vein thromboses associated with myeloproliferative neoplasms: an international, retrospective study on 518 cases","volume":"95","author":"Sant\u2019Antonio","year":"2020","journal-title":"Am. J. Hematol."},{"issue":"3","key":"10.1016\/j.thromres.2022.01.011_bb0105","doi-asserted-by":"crossref","first-page":"e338","DOI":"10.1055\/s-0041-1733856","article-title":"Is hematopoietic clonality of indetermined potential a risk factor for pulmonary embolism?","volume":"5","author":"Soudet","year":"2021","journal-title":"TH Open"},{"issue":"5","key":"10.1016\/j.thromres.2022.01.011_bb0110","doi-asserted-by":"crossref","first-page":"317","DOI":"10.7326\/M17-0028","article-title":"Risk for arterial and venous thrombosis in patients with myeloproliferative neoplasms: a population-based cohort study","volume":"168","author":"Hultcrantz","year":"2018","journal-title":"Ann. Intern. Med."},{"issue":"9","key":"10.1016\/j.thromres.2022.01.011_bb0115","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1038\/leu.2013.163","article-title":"Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study","volume":"27","author":"Tefferi","year":"2013","journal-title":"Leukemia."},{"issue":"11","key":"10.1016\/j.thromres.2022.01.011_bb0120","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/s41408-018-0143-y","article-title":"Targeting myeloid cells to prevent recurrent stroke in general population: the lesson of hydroxyurea in myeloproliferative neoplasms","volume":"8","author":"Barbui","year":"2018","journal-title":"Blood Cancer J."},{"issue":"11","key":"10.1016\/j.thromres.2022.01.011_bb0125","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/s41408-018-0151-y","article-title":"Hydroxyurea prevents arterial and late venous thrombotic recurrences in patients with myeloproliferative neoplasms but fails in the splanchnic venous district. Pooled analysis of 1500 cases","volume":"8","author":"De Stefano","year":"2018","journal-title":"Blood Cancer J."}],"container-title":["Thrombosis Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384822000111?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384822000111?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T17:46:46Z","timestamp":1758736006000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049384822000111"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":25,"alternative-id":["S0049384822000111"],"URL":"https:\/\/doi.org\/10.1016\/j.thromres.2022.01.011","relation":{},"ISSN":["0049-3848"],"issn-type":[{"value":"0049-3848","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"JAK2 allele burden is correlated with a risk of venous but not arterial thrombosis","name":"articletitle","label":"Article Title"},{"value":"Thrombosis Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.thromres.2022.01.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}